← Browse by Condition
Medical Condition

rare unresectable or metastatic braf v600e mutation positive solid tumors

Total Trials
1
Recruiting Now
1
Trial Phases
Various
NCT05868629
Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Enrollment
40 pts
Location
United States
Sponsor
Novartis Pharmaceuticals
View Trial →